Tricuspid regurgitation and additional cardiac amyloidosis: early diagnosis and treatment to prevent disease progression

Tricuspid regurgitation and additional cardiac amyloidosis: early diagnosis and treatment to prevent disease progression - TRICAM

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00039996

Enrollment

600

Registered

2026-04-22

Start date

2026-05-01

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I36.1 E85

Interventions

Group 1: Patients with and without cardiac amyloidosis (CA) and tricuspid regurgitation (TR)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with cardiac amyloidosis (CA) Patients with tricuspid regurgitation (TR) First presentation between January 1, 2015, and December 31, 2025

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
(i) mortality and causes of death in patients with cardiac amyloidosis (CA) and tricuspid regurgitation (TR), (ii) prevalence, etiology, and prognostic impact of TR in CA on mortality, and (iii) diagnostic and therapeutic strategies for TR in patients with CA compared with patients without confirmed CA.	—

Countries

Germany

Contacts

Public ContactIsabel Mattig

Deutsches Herzzentrum der Charité

isabel.mattig@dhzc-charite.de+49 30 450 513 142

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: May 1, 2026